Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

Overview of attention for article published in Oncologist, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

policy: 2 policy sources
twitter: 10 X users

facebook: 1 Facebook page

Readers on

mendeley: 28 Mendeley

So far, Altmetric has seen 12 X posts from 10 X users, with an upper bound of 17,197 followers.

RT @JTrentMDPhD: Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An An…

RT @schoffski: Ripretinib dose escalation to 150 mg b.i.d provides additional clinical benefit when 4th line GIST patients progress on stan…

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study - Zalcberg - 2021 - The Oncologist - Wiley Online Library https://t.co/vK8xd0LnFE

RT @schoffski: Ripretinib dose escalation to 150 mg b.i.d provides additional clinical benefit when 4th line GIST patients progress on stan…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.